Dual Antiplatelet Therapy After Drug-Eluting Stents Implantation in East Asians: A Network Meta-Analysis of Randomized Controlled Trials. Issue 2 (August 2022)

• Record Type: Journal Article
• Authors: Zhong, Peng-Yu; Shang, Yao-Sheng; Bai, Nan; Ma, Ying; Niu, Ying; Wang, Zhi-Lu
• Is Part Of: Journal of cardiovascular pharmacology. Volume 80:Issue 2(2022)
• Page Start: 216
• Page End: 225
• Publication Date: 2022-08
• Subjects: acute coronary syndrome -- percutaneous coronary intervention -- drug-eluting stents -- dual antiplatelet therapy; Cardiovascular Diseases -- drug therapy -- Periodicals; Cardiovascular System -- drug effects -- Periodicals; Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular agents; Cardiovascular pharmacology; Periodicals; 615.7105
• DOI: 10.1097/FJC.0000000000001288
• Languages: English
• ISSNs: 0160-2446

Abstract

Abstract : Supplemental Digital Content is Available in the Text. Abstract: Dual antiplatelet therapy (DAPT) is essential to prevent the risk of ischemia events, but it is difficult to avoid concurrent bleeding events. East Asians are associated with a higher tendency of bleeding than Caucasians, which may affect the DAPT duration. Therefore, this network meta-analysis to explore optimum DAPT duration for East Asians. The related randomized controlled trials that compared the different DAPT duration in East Asian patients were included by searching PubMed, EMBASE, and Cochrane Library database. The outcomes included myocardial infarction, stent thrombosis, all-cause death, stroke, and major bleeding. In addition, net adverse cardiac and cardiovascular events was defined as a composite outcome in this study. We calculated the odds ratio (OR) and 95% confidence intervals for end point events by the fixed effects model in the Bayesian's network frame. We included a total of 12 randomized controlled trials with 30, 640 patients. Compared with 12-month DAPT, 1- to 3-month DAPT is effective in myocardial infarction (OR 0.72, 0.46–1.08), stents thrombosis (OR 1.27, 0.59–2.84), all-cause death (OR 0.91, 0.65–1.28), and stroke (OR 0.89, 0.57–1.39). The 1- to 3-month DAPT was associated with a lower risk of major bleeding compared with 12-month DAPT (OR 0.55, 0.4–0.76), 6-month DAPT (OR 0.54, 0.31–0.94), and >12-month DAPT (OR 0.43, 0.28–0.65). In addition, more than 12 months of DAPT did not reduce the incidence of myocardial infarction (OR 0.75, 0.51–1.11) and increased the risk of major bleeding (OR 1.28, 0.88–1.87) compared with 12-month DAPT. The 1- to 3-month DAPT was more secure and effective than the other 3 DAPT strategies. Although East Asians have a higher risk of bleeding, more than 12 months of DAPT does not increase this incidence of major bleeding.